2023 World Conference on Lung Cancer (Posters)-P2.10. Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L

P2.10. Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L - PDF(Abstract)

Back to course

Pdf Summary

This presentation at the WCLC 2023 conference focused on the correlation between clinical benefits and health-related quality of life (HRQoL) in patients with ALK non-small cell lung cancer (NSCLC) who received first-line therapy with brigatinib or crizotinib. The ALTA-1L trial was mentioned, where brigatinib demonstrated superior efficacy compared to crizotinib in terms of median progression-free survival (PFS) and delayed time to worsening in global health status/quality of life (GHS/QoL). <br /><br />The study included patients with baseline and post-baseline GHS values, and responders were defined as those who had a complete or partial response according to the blinded independent review committee. Worsening of HRQoL was measured using the EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) scores. Time to worsening (TTW) analyses were conducted for responders and non-responders, and differences between response groups were analyzed using Kaplan-Meier methods.<br /><br />The results showed that responders had significantly longer TTW for GHS/QoL scores and were less likely to experience worsening compared to non-responders, regardless of treatment (brigatinib or crizotinib). Brigatinib responders had a further delayed TTW in HRQoL compared to crizotinib responders, indicating a better quality response with first-line brigatinib treatment in ALK NSCLC. <br /><br />Overall, the study suggested that responders to both treatments had improved HRQoL outcomes compared to non-responders in various domains. Brigatinib-treated responders had better HRQoL outcomes compared to crizotinib-treated responders, suggesting a superior quality response with brigatinib as a first-line therapy for ALK NSCLC.

Asset Subtitle

Rosario García-Campelo

Meta Tag

Speaker Rosario García-Campelo

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

WCLC 2023 conference

clinical benefits

HRQoL

ALK non-small cell lung cancer

brigatinib

crizotinib

ALTA-1L trial

progression-free survival

GHS/QoL

quality response